Company news

Alkermes plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

August 29, 2023

Alkermes plc Reports Second Quarter 2023 Financial Results

July 25, 2023

Alkermes to Report Second Quarter Financial Results on July 26, 2023

July 18, 2023

Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders

June 28, 2023

Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote "FOR" All Seven of the Company's Highly Qualified Director Nominees

June 20, 2023

Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board

June 19, 2023

Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors

June 12, 2023

Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation

June 7, 2023

Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations

June 5, 2023

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

May 31, 2023

Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value

May 24, 2023

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences

May 15, 2023

Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 8, 2023

Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process

May 7, 2023

Alkermes plc Reports First Quarter 2023 Financial Results

April 25, 2023

Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration

April 24, 2023

Alkermes to Report First Quarter Financial Results on April 26, 2023

April 18, 2023

Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer

April 18, 2023

Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business

April 17, 2023

Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness

March 22, 2023

Alkermes to Participate in the Stifel 2023 CNS Days

March 14, 2023

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023

February 15, 2023

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023

February 8, 2023

Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

January 16, 2023

Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 27, 2022

Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference

November 29, 2022

Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference

November 21, 2022

Alkermes to Participate in the Stifel Healthcare Conference

November 7, 2022

Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants(R) Program

November 6, 2022

Alkermes Celebrates Hispanic Americans Who Are Trailblazers in the Mental Health Field

November 2, 2022

Alkermes plc Reports Third Quarter 2022 Financial Results

November 1, 2022

Alkermes plc Announces Intent to Separate Oncology Business

November 1, 2022

A Message on Corporate Responsibility From Richard F. Pops, Alkermes CEO

October 31, 2022

Alkermes Named Awardee of NEEBC's Best Practices Award 2021

October 27, 2022

Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants® Program

October 26, 2022

Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022

October 25, 2022

Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program

September 27, 2022

Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress

September 19, 2022

Alkermes plc Reports Second Quarter 2022 Financial Results

July 26, 2022

Alkermes to Report Second Quarter Financial Results on July 27, 2022

July 19, 2022

Alkermes Announces Results of Annual General Meeting of Shareholders

July 6, 2022

Alkermes to Participate in the Goldman Sachs Healthcare Conference

June 7, 2022

Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer

June 1, 2022

Alkermes to Participate in the Jefferies Healthcare Conference

May 31, 2022

Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2022

Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors

May 25, 2022

Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 8, 2022

Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month

May 1, 2022

Alkermes plc Reports First Quarter 2022 Financial Results

April 26, 2022

Alkermes to Report First Quarter Financial Results on April 27, 2022

April 19, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 73 decks. Every deck is listed under its year.